The study will focus on relieving abdominal pain in IBS patients over 21 through psychotherapy. It will measure effects on patients at four weeks, six months and 12 months.
The study will be led by MGH pediatric gastroenterology fellow Erin Mauney, MD.
“We are delighted to be partnering with Tryp Therapeutics, a recognized leader in the development of psilocybin-assisted therapies,” Dr. Mauney said in a Jan. 3 press release. “There is tremendous potential for the treatment of debilitating IBS and other disorders of gut-brain interaction by utilizing the combined administration of psilocybin and psychotherapy.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.